Improving lives and health outcomes.

David Loew was appointed as Chief Executive Officer of Ipsen on July 1, 2020.

David brings nearly 30 years of leadership and experience across a range of therapeutic areas, including oncology, CNS and cardio-metabolism, as well as consumer healthcare. He has worked in the U.S., European and international markets. He began his career at Coopers & Lybrand and Hewlett Packard in 1990 before joining Roche in 1992. Over the following two decades, David held a variety of positions, including Global Oncology Head, Global Chief Marketing Officer & Head of Global Product Strategy and Region Head, Eastern Europe, Middle East and Africa for the Pharma Division of Roche. He joined Sanofi in July 2013 as Senior Vice President, Commercial Operations Europe, where he was responsible for the prescription, consumer healthcare and generics business across the EU region. In 2016, David was appointed CEO of Sanofi Pasteur Vaccines.

David currently serves on the Boards of the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA), the European Federation of Pharmaceutical Industries and Associations (EFPIA), and G5 Santé, the federation of French pharmaceutical companies.

David earned his BA in Business Administration and MBA from the University of St. Gallen, Switzerland.

Catherine Abi-Habib joined Ipsen in 2022
as Executive Vice President, Strategy, Transformation and Digital.

Prior to joining Ipsen, Catherine spent more than 10 years working with pharmaceutical and biotech companies, health systems, payors, providers, and charitable foundations. She joined Ipsen from McKinsey, where she was a Partner in the Life Sciences practice based in London. Working closely with QuantumBlack, McKinsey’s advanced analytics firm, she partnered with leading biopharma companies on large-scale digital and analytics driven transformations
across North America, Europe and Asia, focused on improving physician experience.

Catherine holds an MSc. in Economics from the London School of Economics and a BA in Mathematics from the University of Cambridge, Trinity College.

Bartosz (Bartek) Bednarz, DDS joined Ipsen in 2017.

He currently serves as Executive Vice President, Head of Global Product and Portfolio Strategy at Ipsen, which covers Global Franchises, Global Value and Access and Global Strategic Business Excellence.

Before assuming his current role, Bartosz successfully led Ipsen’s oncology franchise. Prior to that, he held global leadership roles at AstraZeneca and Novartis. At AstraZeneca, where Bartosz spent seven years, he started as Country President and later led new launches in oncology as well as Oncology Commercial Operations at a global level while based in Cambridge (UK). At Novartis, Bartosz held various commercial leadership roles at local, regional and international levels around the world, including Poland, Spain, Switzerland and Canada. He has worked across multiple therapeutic areas and is very passionate about Ipsen’s focus in oncology, rare disease and neuroscience.

Bartosz Bednarz holds a Doctor of Dental Medicine, and he obtained his diploma with honors at the Medical University of Pomerania in Poland.

Stewart Campbell was appointed Executive Vice President and President of North America in November 2021.

Stewart joined Ipsen as Senior Vice President and Franchise Head of Oncology in May 2021 from Roche/Genentech where he spent more than 14 years, responsible for the lifecycle management of some of Roche’s oncology blockbusters, including both commercial and clinical development globally. Through a career of more than 20 years in the pharmaceutical industry, Stewart has deep experience leading country and global commercial functions in oncology and specialty care markets, including Canada, Switzerland, and the United States.

Stewart is a graduate of Concordia University in Montreal, Canada, where he received his B.S. in physiology with a minor in physics. He received his MBA in corporate finance from Queens University in Kingston, Canada and an additional MBA in business strategy from the Johnson School of Management at Cornell University in Ithaca, New York.

François Garnier was appointed Executive Vice President, General Counsel in December 2014.

François began his career in 1989 at Servier S.A. as International Contracts Manager and remained with the company until September 1995. He then moved to Rhône Poulenc Rorer S.A. to take up the position of Counsel for Corporate Transactions. In 1996 he moved to the United States as Associate Counsel, before being appointed Chief Counsel for France in 1999. François continued his career as Chief Counsel at Aventis Animal Nutrition until 2001, when he joined the Pharmacia Group as Chief Counsel for Europe.

François joined Pfizer France in 2003, as Vice-President, General Counsel before moving on to become Chief Counsel for Pfizer’s operations in Europe from 2009 to 2014. He was International Chief Counsel (ex-US) for Pfizer Inc. from January 2014.

A student from the IEP in Paris, Francois graduated from the University of Panthéon-Assas.

Steven Hildemann, M.D., Ph.D. joined Ipsen in March 2020 as Chief Medical Officer.

Prior to joining Ipsen, Steven held leadership roles in science-based bioethics and built an innovative digital health startup in cancer care after serving for five years as Chief Medical Officer, Senior Vice President, Head of Global Medical Affairs and Global Patient Safety at Merck. He also held several strategic leadership positions with biopharmaceutical companies such as Pharmacia-Pfizer and Schering-Plough-MSD.

Steven is board certified in internal medicine and cardiology with broad clinical training across internal medicine including medical oncology, gastroenterology, rheumatology and pulmonary oncology at university hospitals in Munich, Germany. Throughout his career, he has engaged in part-time clinical practice, late-stage pharmaceutical research and medical teaching. Steven received his M.D., Ph.D. at the Albert Ludwig University of Freiburg, Germany, where he continues to serve as an adjunct Professor of Medicine.

Aymeric Le Chatelier was appointed Executive Vice President, Group Chief Financial Officer in November 2014.

Aymeric, a graduate from HEC Business School, started his career at Arthur Andersen. He successively executed several roles in finance in France and the United States at Veolia. He then joined Arjowiggins, a leading manufacturer of creative and technical paper, as Group Chief Financial Officer. He was subsequently appointed Financial Director of Enedis and member of the Management Board.

Aymeric served as interim Chief Executive Officer of the Group from 1 January 2020 until David Loew was appointed Chief Executive Officer in July 2020.

Philippe Lopes-Fernandes joined Ipsen in October 2020 as Executive Vice President, Chief Business Officer.

With more than 20 years of leadership and expertise in global business development and acquisitions within the pharmaceutical industry, Philippe is responsible for driving Ipsen’s external innovation strategy and strengthening alliances across its key therapeutic areas of oncology, neuroscience and rare disease. He has an extensive track record of creating successful business development deals in multiple therapeutic areas in Europe, Asia and North America.

Prior to joining Ipsen, Philippe worked at Merck KGaA where he was the Senior Vice President, Global Head of Business Development and Alliance Management. Before that, he held a variety of roles at Merck KGaA in Business Development, Mergers & Acquisitions, Finance and Marketing in Germany, France, Portugal, Switzerland and the United States.

Philippe received his degree from the Institut Supérieur de Gestion (ISG) in Paris in 1994. He is a French External Trade advisor (Conseiller du Commerce Extérieur) and board member of several companies.

Howard Mayer, M.D. joined Ipsen in December 2019 as Executive Vice President, Head of Research and Development.

Howard joined Ipsen from Shire, where he was Chief Medical Officer, responsible for the hematology, immunology, oncology, genetic diseases, GI/metabolic, neuroscience and ophthalmology therapeutic areas.

Previously, he served as Chief Medical Officer at EMD Serono, a division of Merck KGaA. Prior to that, he held a variety of global roles at Pfizer, including Head, Clinical Development and Medical Affairs for Virology/Infectious Diseases. Prior to joining Pfizer, he served as Director of Clinical Research at Bristol-Myers Squibb.

Howard obtained his B.A. from the University of Pennsylvania and his M.D. from Albert Einstein College of Medicine, which was followed by an internship and residency at Mount Sinai Hospital and an Infectious Diseases fellowship at Harvard Medical School. He currently serves on the board of directors for Genocea Biosciences and Entasis Therapeutics, and on the board of Autism Speaks in New England. He was honored by PharmaVoice as one of the 100 Most Inspiring People in the Life Sciences Industry in both 2011 and 2017.

Régis Mulot joined Ipsen in March 2018 as Executive Vice President, Chief Human Resources Officer.

Prior to joining Ipsen, Régis served as Executive Vice President, Chief Human Resources Officer at Staples Inc., the global specialty retail and e-commerce company and led a global team of over 600 professionals. Prior to his career with Staples (2009-18), Régis held HR leadership positions with Levi Strauss & Co (2002-08) and the technology start-up Broadnet Europe (2000-02), following earlier roles at GTECH Corporation (1994-2000), International Post Corporation (1991-94) and Chronopost SA (1989-91).

Régis served on the Board of Trustees, Simmons College (Boston, MA, USA); is Past Chairman of the Business Advisory Committee of the Simmons School of Management 2014-2017; Founder and former chair of the French-American HR Forum since 2016-2018. He has been co-chair of the Boston CHRO (Chief Human Resources Officers) Leadership summit between 2014 and 2018 and is a Gartner CHRO Leadership Board member since 2017.

Régis holds a DESS Entreprises Publiques (Master in Public Administration) from Paris XI-Sud in partnership with Paris IX-Dauphine and Institut International d’Administration Publique (IIAP). He also holds a Maîtrise Droit Public (Bachelor of Law) from Paris II–Panthéon-Assas and is a Beta Gamma Sigma honoree from the Simmons College Chapter.

Aidan Murphy, Ph.D. was appointed Executive Vice President, Technical Operations in January 2018.

Aidan has more than 25 years’ experience in the pharmaceutical and biotechnology industry, and since joining Ipsen in 2006 has held several manufacturing leadership roles across the globe.

Prior to his current role, Aidan was Senior Vice President, Biologics Development and Manufacturing, and has also led Ipsen’s manufacturing sites in Tianjin (China), Dublin (Ireland), and Wrexham (UK) and occupied global roles as SVP CMC (Chemistry, Manufacturing, and Controls) Development & Engineering and Head of Specialty Care Manufacturing. He holds a Ph.D. in organic chemistry from Trinity College, Dublin.

Mari Scheiffele joined Ipsen in November 2021 as EVP and President, International.

Mari brings 20 years of healthcare leadership experience, from across the pharmaceutical industry, having worked in the US, Europe and in Japan. She joined Ipsen from Novartis where she had held both global strategy and country operational roles in Japan and in the UK. Prior to joining Ipsen, Mari was the General Manager, Novartis Oncology UK & Ireland where with a focus on patient-centricity, evidence-based medicine, and partnership, she drove a successful business transformation.

In addition to her focus in oncology, Mari has worked in other specialty care environments such as ophthalmology, neuroscience, and immunology. Prior to Novartis, Mari was a partner at McKinsey & Company in New York and in Switzerland in pharmaceuticals and medical products.

Mari holds a doctorate in neuroscience from Harvard Medical School.

Gwenan White joined Ipsen on March 1, 2021 as Executive Vice President, Communications and Public Affairs.

In her role, Gwenan is responsible for designing, implementing and managing the communications and public affairs strategy for Ipsen. She brings 30 years of experience in pharmaceuticals at global, regional and country roles. Before joining Ipsen, Gwenan was the Global Head of Pharma Communications and Patient Advocacy at Novartis and member of the Pharma Executive Committee. Over the course of her career, she has held a variety of leadership roles of in public affairs, corporate, science and product communications, patient advocacy and marketing at AbbVie, GSK and Schering-Plough.

Gwenan holds a degree in Biochemistry from the University of Liverpool.